|
WO2021076616A1
|
|
Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
|
|
WO2021072210A1
|
|
Methods of purifying ranibizumab or a ranibizumab variant
|
|
WO2021072182A1
|
|
Methods for producing ranibizumab
|
|
WO2021067716A1
|
|
Control mechanism for priming an injection device
|
|
WO2021050687A1
|
|
Stable aqueous formulations of aflibercept
|
|
WO2020243058A1
|
|
Compositions and methods to treat cancer
|
|
WO2020227121A1
|
|
Method of producing a recombinant protein
|
|
WO2020142365A1
|
|
Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
|
|
US2020207823A1
|
|
Process for producing, isolating, and purifying modified recombinant proteins
|
|
WO2020205023A1
|
|
Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
|
|
WO2020205024A1
|
|
Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
|
|
WO2020205025A1
|
|
Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
|
|
US2020207812A1
|
|
Methods for producing recombinant proteins
|
|
US2020246423A1
|
|
Stable aqueous formulations of aflibercept
|
|
US2019298708A1
|
|
Methods of treating subjects with an elevated neurofilament light chain level
|
|
EP3761953A1
|
|
Stable aqueous formulations of aflibercept
|
|
MX2019011867A
|
|
Pparî³ agonist for treatment of progressive supranuclear palsy.
|
|
EP3570841A1
|
|
PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE
|
|
US2018043020A1
|
|
Method of reducing immunogenicity of drug products
|
|
US2017304445A1
|
|
Method of filling a container with no headspace
|
